Skip to Main Content
Important information:
Important Information Regarding Medicare Advantage Plans – Learn More.
  • Sylvester Comprehensive Cancer Center |
  • Bascom Palmer Eye Institute
University of Miami Health
  • Appointments
  • Pay a Bill
  • Refer a Patient
  • International Patients
  • Donate Now
  • Search
  • Patient Login
  • Find a Doctor
  • Treatments Page 1
    Featured Treatments For
    • Allergy and Immunology
    • Arthritis (Rheumatology)
    • Bariatrics (Weight Loss Surgery)
    • Cancer (Oncology)
    • Cardiac and Vascular
    • Concierge Medicine
    • Dentistry
    • Dermatology
    • Diabetes
    • Ear, Nose, and Throat (ENT)
    • Emergency Care
    • Endocrinology, Diabetes and Metabolism
    • Executive Physicals
    • Eye Care (Ophthalmology)
    • Fertility Center
    • Gastrointestinal
    • Genetics
    • Geriatrics
    • Hepatology
    • High Blood Pressure (Hypertension)
    • Hyperbaric Oxygen Therapy
    • Infectious Diseases
    • Internal Medicine
    • Interventional Radiology
    • Lymphedema
    • Nephrology
    • Neurology
    • Neurosurgery
    • Obstetrics and Gynecology
    • Orthopaedics
    • Pain Management and Palliative Care
    • Pediatrics
    • Physical Medicine and Rehabilitation
    • Plastic Surgery
    • Primary Care
    • Psychiatry
    • Pulmonary Medicine
    • Radiology
    • Sleep Medicine
    • Sports Medicine Institute
    • Surgery
    • Transplant
    • UHealth Comprehensive Women’s Health Alliance
    • UHealth Premier
    • Urology
    View all Treatments
    Browse A-Z A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
    Featured Treatments For
    • Allergy and Immunology
    • Arthritis (Rheumatology)
    • Bariatrics (Weight Loss Surgery)
    • Cancer (Oncology)
    • Cardiac and Vascular
    • Concierge Medicine
    • Dentistry
    • Dermatology
    • Diabetes
    • Ear, Nose, and Throat (ENT)
    • Emergency Care
    • Endocrinology, Diabetes and Metabolism
    • Executive Physicals
    • Eye Care (Ophthalmology)
    • Fertility Center
    • Gastrointestinal
    • Genetics
    • Geriatrics
    • Hepatology
    • High Blood Pressure (Hypertension)
    • Hyperbaric Oxygen Therapy
    • Infectious Diseases
    • Internal Medicine
    • Interventional Radiology
    • Lymphedema
    • Nephrology
    • Neurology
    • Neurosurgery
    • Obstetrics and Gynecology
    • Orthopaedics
    • Pain Management and Palliative Care
    • Pediatrics
    • Physical Medicine and Rehabilitation
    • Plastic Surgery
    • Primary Care
    • Psychiatry
    • Pulmonary Medicine
    • Radiology
    • Sleep Medicine
    • Sports Medicine Institute
    • Surgery
    • Transplant
    • UHealth Comprehensive Women’s Health Alliance
    • UHealth Premier
    • Urology
    View all Treatments
  • Locations
  • Patients & Families
    Quick links
    • Appointments
    • Pay a Bill
    • Make a Gift
    • Insurance Plans Accepted
    • MyUHealthChart
    • Advance Directives
    For Patients & Families
    • Your First Visit
    • Medical Records
    • Frequently Asked Questions
    • Patient and Caregiver Resources
    • Patients & Families
    • Public Transportation
    • UHealth Clinic at Walgreens
    • Classes & Events
    • Support Groups
    • Interpreter Services
    • International Patients
    • UMiami Health Talks
    About Uhealth
    • Why Choose UHealth
    • Benefits of an Academic Medical Center
    • Mission & Values
    • Leadership
    • Community Health Improvement
    • Nursing at UHealth
    • Health News
    • Miller School of Medicine
    • University of Miami
    • Careers
    • Volunteers
    • Contact Us
    Clinical Trials
    • Find a Clinical Trial
    • Understanding Clinical Trials
    • Clinical Trials FAQ's
    Traveling from overseas?
    We can help plan your visit. Learn More
    Quick links
    • Appointments
    • Pay a Bill
    • Make a Gift
    • Insurance Plans Accepted
    • MyUHealthChart
    • Advance Directives
    For Patients & Families
    • Your First Visit
    • Medical Records
    • Frequently Asked Questions
    • Patient and Caregiver Resources
    • Patients & Families
    • Public Transportation
    • UHealth Clinic at Walgreens
    • Classes & Events
    • Support Groups
    • Interpreter Services
    • International Patients
    • UMiami Health Talks
    About Uhealth
    • Why Choose UHealth
    • Benefits of an Academic Medical Center
    • Mission & Values
    • Leadership
    • Community Health Improvement
    • Nursing at UHealth
    • Health News
    • Miller School of Medicine
    • University of Miami
    • Careers
    • Volunteers
    • Contact Us
    Clinical Trials
    • Find a Clinical Trial
    • Understanding Clinical Trials
    • Clinical Trials FAQ's
Patient Login
  • University of Miami Health System
  • Clinical Trials
  • A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML)

A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML)

Principal Investigator

Antonio Jimenez

Enrollment Status

Closed

Clinical Trial ID

Institutional Protocol # 20170757
National Clinical Trials Identifier NCT02997202

Clinical Trial Summary

The purpose of this study is to compare relapse-free survival between participants with
FLT3/ITD AML in first morphologic complete remission (CR1) who undergo hematopoietic stem
cell transplant (HCT) and are randomized to receive gilteritinib or placebo beginning after
the time of engraftment for a two year period.


Phase

Phase 3


Funding Agency/Sponsor

National Cooperative Group


Disease

Leukemia


Enrollment Eligibility

Registration Inclusion Criteria
- Participant is considered a suitable candidate for HCT and has an acceptable source of
allogeneic donor stem cells, as defined per institutional practice (allogeneic HCT for
any donor source [matched sibling, unrelated donor (URD), mismatched URD, related
haploidentical, or umbilical cord blood] and any graft source [umbilical cord, BM,
peripheral blood (PB)], and any conditioning [myeloablative conditioning (MAC),
reduced intensity conditioning (RIC), or non-myeloablative conditioning (NMA)] will be
permitted).
- Participant is considered a legal adult by local regulation at the time of signing
informed consent form (ICF).
- Participant consents to allow access to diagnostic BM aspirate or PB sample and/or the
DNA derived from that sample, if available, that may be used to validate a companion
diagnostic that is being developed in parallel with gilteritinib.
- Participant has confirmed, morphologically documented AML in CR1. For the purposes of
registration, CR1 will be defined as < 5% blasts in the BM with no morphologic
characteristics of acute leukemia (e.g., Auer Rods) in the BM with no evidence of
extramedullary disease such as central nervous system involvement or granulocytic
sarcoma.
- Participant has not received more than 2 cycles of induction chemotherapy to
achieve CR1. The induction cycles can be the same regimen or different regimens.
The regimen(s) may contain conventional agents, investigational agents, or a
combination of both.
- Participants with CR with incomplete count recovery (CRp or CRi) are allowed.
Incomplete platelet recovery (CRp) is defined as CR with platelet count < 100 x
109/L. Incomplete blood count recovery (CRi) is defined as CR with residual
neutropenia < 1 x 109/L with or without complete platelet recovery. Red blood
cell count (RBC) and platelet transfusion independence is not required.
- The maximum time allowed from establishment of CR1 to registration is 12 months.
- Participant has presence of the FLT3/ITD activating mutation in the BM or PB as
determined by the local institution at diagnosis.
- Participant must meet the following criteria as indicated on the clinical laboratory
tests:
- Serum creatinine within normal range, or if serum creatinine outside normal
range, then glomerular filtration rate (GFR) > 40 mL/min/1.73m2 as calculated
with the Cockcroft-Gault equation with adjustment if total body weight is ≥ 125%
of ideal body weight.
- Total bilirubin (TBL) ≤ 2.5 mg/dL, except for participants with Gilbert's
syndrome.
- Serum AST and/or alanine aminotransferase (ALT) < 3 x institutional upper limit
of normal (ULN).
- Participant has left ventricular ejection fraction at rest ≥ 40%.
- Participant has diffusing capacity of the lung for carbon monoxide (DLCO) (corrected
for hemoglobin) ≥ 50% predicted and/or forced expiratory volume in 1 second (FEV1) ≥
50% predicted.
- Female participants must either:
- Be of non-childbearing potential:
- postmenopausal (defined as at least 1 year without menses) prior to screening or
- documented as surgically sterilized (at least 1 month prior to the screening
visit)
- Or, if of childbearing potential,
- Agree not to try to become pregnant during the study for 6 months after the final
study drug administration
- And have a negative serum pregnancy test at screening
- And, if heterosexually active, agree to consistently use highly effective
contraception per locally accepted standards in addition to a barrier method
starting at screening and throughout the study period and for 6 months after the
final study drug administration.
- For United Kingdom sites:
- Highly effective forms of birth control include:
- Consistent and correct usage of established hormonal contraceptives that inhibit
ovulation
- Established intrauterine device (IUD) or intrauterine system (IUS)
- Female participants must agree not to breastfeed or donate ova throughout the study
drug treatment period and for 6 months after the final study drug administration.
- Male participants (even if surgically sterilized), and partners who are women of
childbearing potential must be using highly effective contraception in addition to a
barrier method throughout the study drug treatment period and for 127 days after the
final study drug administration.
- For United Kingdom sites:
- Highly effective forms of birth control include:
- Consistent and correct usage of established hormonal contraceptives that inhibit
ovulation
- Established IUD or IUS
- Vasectomy (A vasectomy is a highly effective contraception method provided the
absence of sperm has been confirmed. If not, an additional highly effective
method of contraception should be used.)
- Male is sterile due to a bilateral orchiectomy
- Male participants must not donate sperm throughout the study drug treatment period and
for 127 days after the final study drug administration.
- Participant is able to take an oral medication.
- Participant agrees not to participate in another interventional study while on
treatment.
Randomization Inclusion Criteria
- Participant is ≥ 30 days and ≤ 90 days from hematopoietic cell infusion.
- Participant has achieved engraftment. Engraftment is defined as ANC ≥ 500 cells/μL and
platelets ≥ 20000/μL on 3 consecutive measurements (each occurring at least 1 day
apart). The participant must not have had a platelet transfusion within 7 days prior
to the first measurement.
- Participant has confirmed ongoing morphologically documented AML in CR1. For the
purposes of randomization, CR1 will be defined as < 5% blasts with no morphologic
characteristics of acute leukemia (e.g., Auer Rods) in the BM with no evidence of
extramedullary disease such as central nervous system involvement or granulocytic
sarcoma.
- Participant meets the following criteria as indicated on the clinical laboratory
tests:
- Serum creatinine within normal range, or if serum creatinine outside normal
range, then GFR > 40 mL/min/1.73m2 as calculated with the Cockcroft-Gault
equation with adjustment if total body weight is ≥ 125% of ideal body weight.
- TBL < 2.5 mg/dL, except for participants with Gilbert's syndrome.
- Serum AST and/or ALT < 3 x institutional ULN.
- Serum potassium and magnesium ≥ the institutional lower limit of normal (LLN).
- If the participant has developed overall grades II-IV acute GVHD, the following
criteria must be met to be randomized:
- No requirement of > 0.5 mg/kg of prednisone (or equivalent) daily dose within 1
week of randomization
- No escalation of systemic immunosuppression in terms of increase of
corticosteroids or addition of new agent / modality within 2 weeks of
randomization. (Note that increasing calcineurin inhibitors or sirolimus to
achieve therapeutic trough levels is allowed.) Topical skin and topical
gastrointestinal steroids are allowed.
- Participant is able to take oral medication.
Registration Exclusion Criteria
- Participant has had a prior allogeneic transplant.
- Participant has Karnofsky performance status score < 70% .
- Participant requires treatment with concomitant drugs that are strong inducers of
CYP3A within 14 days of start of study drug.
- Participant requires treatment with concomitant drugs that target serotonin
5-hydroxytryptamine receptor 1 (5HT1R) or 5-hydroxytryptamine receptor 2B (5HT2BR) or
sigma nonspecific receptor with the exception of drugs that are considered absolutely
essential for the care of the participant.
- Participant has a Fridericia-corrected QT interval (QTcF) > 450 msec (average of
triplicate determinations) per central read.
- Participant has long QT Syndrome at screening.
- Participant has a known infection with human immunodeficiency virus (HIV).
- Participant has active hepatitis B infection as determined by NAAT or surface antigen
assay. Participants who have acquired immunity from past exposure (HBcAb positive /
HBsAb positive / HBsAg negative) are eligible.
- Participant has active hepatitis C infection as determined by NAAT. NAAT must be
performed if the participant has positive serology for hepatitis C. Participants who
have had past exposure and have no detectable virus either through spontaneous
clearance or treatment are eligible.
- Participant has an uncontrolled infection. If a bacterial or viral infection is
present, the participant must be receiving definitive therapy and have no signs of
progressing infection for 72 hours prior to registration. If a fungal infection is
present, the participant must be receiving definitive systemic anti-fungal therapy and
have no signs of progressing infection for 1 week prior to registration.
- Progressing infection is defined as hemodynamic instability attributable to
sepsis or new symptoms, worsening physical signs or radiographic findings
attributable to infection.
- Persisting fever without other signs or symptoms will not be interpreted as
progressing infection.
- Participant has had a myocardial infarction within 6 months prior to registration or
New York Heart Association (NYHA) Class III or IV heart failure, uncontrolled angina,
severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute
ischemia.
- Participant has a serious medical or psychiatric illness likely to interfere with
participation in this clinical study.
- Participant is breast feeding or pregnant.
- Participant has prior malignancies, except lobular breast carcinoma in situ, fully
resected basal cell or squamous cell carcinoma of skin or treated cervical carcinoma
in situ.
Cancer treated with curative intent ≥ 5 years previously will be allowed. Cancer treated
with curative intent < 5 years previously will not be allowed.
Randomization Exclusion Criteria
- Participant requires treatment with concomitant drugs that are strong inducers of
CYP3A within 14 days of starting study drug.
- Participant requires treatment with concomitant drugs that target serotonin 5HT1R or
5HT2BR or sigma nonspecific receptor with the exception of drugs that are considered
by the investigator to be absolutely essential for the care of the participant and for
which no acceptable alternative exists.
- Participant has a QTcF interval > 450 msec (average of triplicate determinations) by
central read.
- Participant has a need for supplemental oxygen with the exception of using previously
existing non-invasive continuous positive airway pressure (CPAP) at night.
- Participant has used investigational agents within 4 weeks of randomization.
- Participant has used experimental therapy for acute GVHD within 4 weeks of
randomization. If unsure of the definition of "experimental", discussion with one of
the protocol chairs is recommended.
- Participant has an uncontrolled infection. If a bacterial or viral infection is
present, the participant must be receiving definitive therapy and have no signs of
progressing infection for 72 hours prior to randomization. If a fungal infection is
present, the participant must be receiving definitive systemic anti-fungal therapy and
have no signs of progressing infection for 1 week prior to randomization.
- Progressing infection is defined as hemodynamic instability attributable to
sepsis or new symptoms, worsening physical signs or radiographic findings
attributable to infection.
- Persisting fever without other signs or symptoms will not be interpreted as
progressing infection.


Contact Information

Phone Number +1 (305) 2434624
Get detailed information on ClinicalTrials.Gov

logo
alt="Twitter Logo">
USNWR Best Hospitals 2026-2027 USNWR Best Regional Hospitals 2026-2027
Quick links
  • Appointments
  • Find a Doctor
  • Pay a Bill
  • Insurance Plans Accepted
  • MyUHealthChart
  • Make a Gift
Patient & Families
  • Frequently Asked Questions
  • Medical Records
  • Interpreter Services
  • Clinical Trials
  • International Patients
  • UHealth Clinic at Walgreens
  • Support Groups
  • Price Transparency
  • Florida Health Finder
Healthcare Professionals
  • Refer a Patient
  • Physician & Executive Recruitment
  • Advanced Practice Providers
  • Immunology & Histocompatibility Laboratory
  • Nursing
  • Sleep Center
  • Sports Medicine Institute
  • Pathology Reference Services
About Uhealth
  • Why Choose UHealth
  • Benefits of an Academic Medical Center
  • Mission & Values
  • Leadership
  • Facts & Figures
  • Community Health Improvement
  • For Media
  • Miller School of Medicine
  • University of Miami
  • Careers
  • Volunteers
  • Supply Chain
  • Contact Us

Medical Disclaimer | Terms of Use | Privacy Statement | HIPAA Notice of Privacy Practices | Non-Discrimination Policy | No Surprises Billing Rights
© 2026 University of Miami Health System. All rights reserved.